Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a biopharmaceutical company, is focused on developing novel therapeutics based on RNA interference, or RNAi. By applying its therapeutic expertise in RNAi, the company intends to address substantial medical needs, many of which cannot be effectively addressed with small molecules or antibodies, the current major classes of drugs. Alnylam has taken a leadership role in the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. For further information, visit the Company’s web site at www.alnylam.com.